Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
about
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Future of bisphosphonates and denosumab for men with advanced prostate cancer.Recent advances in bone-targeted therapies of metastatic prostate cancerBone health and prostate cancer.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerPreventing bone complications in advanced prostate cancerCirculating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot studyTherapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.Treatment and prevention of bone complications from prostate cancer.Contemporary therapeutic approaches targeting bone complications in prostate cancerTargeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective StudyAndrogen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerThe STAMPEDE trial: paradigm-changing data through innovative trial design.Current approaches to bone-targeted therapy in genitourinary malignanciesManagement of bone metastases in refractory prostate cancer--role of denosumab.Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialNew and emerging therapies for bone metastases in genitourinary cancers.Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Bone-targeted agents: preventing skeletal complications in prostate cancer.Optimal bone health management strategies in patients with prostate cancerBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Long-term remission after multiple bone metastases following cervical cancer: A case report.Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).Radiotherapy for metastatic bone disease: current standards and future prospectus.Burden of metastatic bone disease from genitourinary malignancies.Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.Zoledronic acid use in cancer patients: more than just supportive care?
P2860
Q26752785-5422E8FB-BD73-409F-BA0F-43D420E5D329Q26771537-B68C8D71-ABCB-40DF-BA01-1E1102C26024Q27021268-F273891C-728B-494B-9614-0A15A2A42A20Q27022847-39C5115B-B355-4E99-A483-0EF72419FE0AQ28076646-71FFE677-ED6F-4DEE-88D5-33B12C4C6BB8Q28081996-6D1F079F-B31C-4ECD-AD2B-BDE3F9F0F706Q28087676-922EDC43-154D-4289-9F36-127521EDC3E4Q33583525-25C41B4A-0CF2-4F35-8C63-6228F5DF975AQ33703763-54864A35-52C3-400C-8277-032DF20E7CADQ33977536-7723A27B-A11B-4D7A-A3D9-90D0A57180F5Q34023510-875E04F1-7B32-4D90-992D-DCE64FAFB17CQ34111634-22351E1F-1ACA-4589-976F-DF81B6EB3746Q34294905-D0481D6F-27A8-4ED3-85CF-BBE5247CA335Q34304585-E05E019F-9271-4022-9198-E7EEAE8BD426Q34441944-52C9168C-45C1-43C0-A682-41C4DC600263Q34960778-24BCF823-A8D9-4C7B-AB06-21E0E61ABE91Q35087364-FF620EBA-6A88-4CA9-8987-49BC53AB86E5Q35661057-554C17A8-CFD9-4D36-B0BE-E001384F794CQ35774987-D2F35743-C4E9-4719-AF20-22E37F403DCAQ35865726-4B245E95-EE70-4749-A2C8-16345BCD3C67Q35870578-21EF26AA-523A-49BE-AD6B-A2D402E07A8EQ35925260-BD463496-B4A0-4ED4-B521-07FA92BC38EDQ36163344-0B38F629-FD7F-4B1B-8798-6A85A16BC3A4Q36231718-3EAF5685-1638-4F4F-A7C4-F8514A66C8E5Q36283689-A9485B2C-18AA-44AC-A5B4-5AE282C8D59EQ36471673-DAC47389-7599-4E35-8AEF-570719BFBE0AQ36707077-EE3F3888-BF3F-45BF-A161-4C4B50278BE0Q36804951-063CF2D0-1069-4677-ADF2-8F713BD36CF7Q36866291-5E3CDCA6-F94C-4677-82A5-2860BF758810Q36910469-887EFF49-420C-4974-A876-342924939E07Q37039594-E9D3C730-9DE0-4EFC-A9BA-3CC1B8D6C2A0Q37080734-EE132C76-B8A5-422A-9773-9D97864B8953Q37166534-D394828D-54B1-4472-8B69-09D87C5B7788Q37390319-55693F2D-017F-4B5C-91A6-FE99C0ECA082Q37435181-BEDAD62D-E219-46DD-9F36-E886A29051C7Q37673201-D52FCB0D-BAD9-48F6-9F12-74C9811E90D9Q37752373-7718FA17-0F88-4468-8103-7C89D4EA8925Q37809860-C22A4C5A-B919-4610-A247-AA3F3E2E25BCQ37812612-67384C0D-B6AF-448C-9416-3EB4F44586E7Q37828494-37379227-3593-417C-9225-BC1AEF6F0F3F
P2860
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant therapy with oral sod ...... randomised controlled trials.
@en
Adjuvant therapy with oral sod ...... randomised controlled trials.
@nl
type
label
Adjuvant therapy with oral sod ...... randomised controlled trials.
@en
Adjuvant therapy with oral sod ...... randomised controlled trials.
@nl
prefLabel
Adjuvant therapy with oral sod ...... randomised controlled trials.
@en
Adjuvant therapy with oral sod ...... randomised controlled trials.
@nl
P2093
P2860
P1433
P1476
Adjuvant therapy with oral sod ...... randomised controlled trials.
@en
P2093
David P Dearnaley
Karen Sanders
Mahesh K B Parmar
Malcolm D Mason
P2860
P304
P356
10.1016/S1470-2045(09)70201-3
P577
2009-08-10T00:00:00Z